Biology is learning to leave the body

The body used to come with the product

For most of human history, obtaining a biological product meant keeping the organism that made it. Milk required a mammal. Insulin came from a pancreas. Meat required an animal that had grown muscle, fat, blood vessels, nerves, skin, and everything else needed to keep that muscle alive.

The organism was both product and factory. We rarely separated the two because we could not.

That changed first in ways that now feel ordinary. In 1982, the FDA approved recombinant human insulin, the first approved recombinant protein medicine. Genetically engineered microorganisms could produce the human protein without harvesting it from an animal pancreas.

The dramatic part was not imitation. The protein's production instructions had become portable.

A pancreas had lost its monopoly on making insulin.

Cheese without the animal

Casein is the family of milk proteins that gives conventional cheese much of its structure, including the behavior that lets mozzarella melt and stretch. Plant-based cheese can approximate the experience with starches, oils, and other ingredients, but it does not contain casein unless dairy is added.

New Culture is pursuing a different route. It uses precision fermentation: microorganisms are given genetic instructions for producing targeted proteins, grown in controlled conditions, and separated from the desired output. The company says its process produces animal-free casein that can be used in mozzarella.

The apparent contradiction is useful. The casein can be animal-free in origin and still be a real dairy allergen because the biological identity of the protein matters more than the species of factory that made it.

That distinction also keeps the regulatory story honest. New Culture announced a self-affirmed GRAS conclusion in 2024 following review by an independent expert panel. Under the FDA framework, qualified experts outside government can reach a GRAS conclusion, and notification to FDA is voluntary. This was not an FDA approval. The scientific mechanism is well established; the company's particular safety claim should retain its exact regulatory label.

If a microbe makes a cow protein, the factory changed. The protein did not become a metaphor.

The function travels farther

Precision fermentation asks a microbe to make a molecule. Cultivated meat starts with animal cells and grows cell material outside the animal. Organoids go further still: under the right conditions, stem cells can proliferate, differentiate, and self-organize into three-dimensional structures that reproduce selected features of organs.

These are not interchangeable achievements. Cultured chicken remains animal-cell material. An intestinal or brain organoid is a research model with serious limitations, including incomplete maturity, vascularization, immune context, scale, and reproducibility. Calling every organoid a “mini-organ” can make the accomplishment sound more complete than it is.

Still, the gradient matters:

1. produce one biological molecule outside its original body; 2. grow one type or mixture of animal cells outside the animal; 3. allow cells to reproduce part of a tissue's organization outside the body; 4. eventually, perhaps, coordinate many engineered functions into larger living systems.

The first three already exist in materially different stages of scientific and commercial maturity. The fourth remains a research direction, not an arrival.

Synthetic bodies may arrive in pieces

“Synthetic body” suggests a single cinematic event: a laboratory produces a complete artificial person. Biology is moving by a less theatrical route. Individual capabilities are leaving bodies one by one.

A protein can leave the organ that made it. Muscle cells can leave the animal. A patch of tissue can reproduce part of an organ's behavior in a dish. None of these is a body. Together, they change the engineering question.

The question is no longer only whether humans can construct an organism from the outside in. It is whether enough biological functions can be made portable, reproducible, and compatible that a body eventually becomes something assembled from capabilities rather than inherited as one indivisible package.

That is an inference extended into speculation. Developmental biology is not modular software. Cells change one another through timing, geometry, chemistry, mechanics, and feedback. A body is not a parts catalog, and moving a function outside it often strips away context that made the function work.

But the direction is visible: biology is becoming less tied to the bodies in which humans first encountered it.

The synthetic body may not begin with a body. It may begin when enough of the body's jobs no longer need one.

Origin becomes a design choice

This shift complicates ordinary categories. Is fermentation-made casein dairy if no cow produced it? It is biologically a dairy protein and commercially an animal-free ingredient. Is cultured chicken meat? Regulators treat food made from cultured animal cells as its own production route, while the cells remain derived from animals. Is an organoid an organ? No, but it can perform enough selected behavior to become useful for studying disease or testing treatments.

The categories blur because they once bundled three different questions:

- What is it made of? - What produced it? - What can it do?

Living organisms usually gave the same answer to all three. Biological engineering is pulling them apart.

The consequence is larger than novel cheese. Once function can travel, provenance, ownership, safety, energy use, scale, and control become part of the biology itself. The future may contain fewer clean lines between grown and manufactured, natural and engineered, organism and platform.

The body is not disappearing. Its monopoly is.